Edition:
United Kingdom

Cellular Biomedicine Group Inc (CBMG.OQ)

CBMG.OQ on NASDAQ Stock Exchange Global Market

13.38USD
9:00pm BST
Change (% chg)

$-1.33 (-9.04%)
Prev Close
$14.71
Open
$14.08
Day's High
$14.23
Day's Low
$13.35
Volume
40,038
Avg. Vol
25,685
52-wk High
$25.00
52-wk Low
$9.25

Select another date:

Thu, Sep 27 2018

Photo

Novartis strikes deal with Chinese firm to make Kymriah

ZURICH Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country.

Novartis strikes deal with Chinese firm to make Kymriah

ZURICH Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 (362,663 pounds) gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country.

UPDATE 1-Novartis strikes deal with Chinese firm to make Kymriah

ZURICH, Sept 27 Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country. Local regulations require that Novartis manufactures Kymriah in China if it wants to treat the country's patients with the drug.

Novartis strikes deal with Chinese firm to make Kymriah

ZURICH, Sept 27 Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country.

BRIEF-Cellular Biomedicine Group Enters Into Strategic Licensing And Collaboration Agreement With A Global Leader In Car-T Cell Therapy For Patients In China

* CELLULAR BIOMEDICINE GROUP ENTERS INTO STRATEGIC LICENSING AND COLLABORATION AGREEMENT WITH A GLOBAL LEADER IN CAR-T CELL THERAPY FOR PATIENTS IN CHINA

BRIEF-Cellular Biomedicine Group Qtrly Loss Per Share $0.51

* CELLULAR BIOMEDICINE GROUP REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS

Select another date: